达格列净联合利格列汀在肥胖2型糖尿病患者治疗中的效果及安全性
Efficacy and Safety of Dapagliflozin Combined with Linagliptin in the Treatment of Obese Patients with Type 2 Diabetes Mellitus
戚传福1
作者信息
- 1. 山东省菏泽市郓城县中医医院内分泌科,山东 菏泽 274700
- 折叠
摘要
目的 探讨达格列净联合利格列汀在肥胖2型糖尿病(type 2 diabetes mellitus,T2DM)患者治疗中的效果及安全性.方法 选取2022年1月—2024年1月期间在山东省菏泽市郓城县中医医院接受治疗的80例肥胖T2DM患者,通过不同的治疗方法分组,每组40例.对照组接受达格列净治疗,研究组在对照组基础上联合利格列汀治疗.对比两组血糖、血脂水平及不良反应总发生率.结果 治疗后,研究组的血糖、血脂水平优于对照组,差异有统计学意义(P<0.05);研究组不良反应总发生率为12.50%(5/40),略高于对照组的7.50%(3/40),差异无统计学意义(χ2=0.139,P>0.05).结论 达格列净联合利格列汀治疗肥胖T2DM患者相较于单独使用达格列净,能更有效地改善患者的血糖和血脂水平,且安全性相当,未明显增加不良反应风险.
Abstract
Objective To investigate the efficacy and safety of dapagliflozin combined with linagliptin in the treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods From January 2022 to January 2024,80 obese T2DM patients who were treated in Yuncheng County Hospital of Traditional Chinese Medicine of Heze City in Shan-dong Province were selected and divided into groups by different treatment methods,with 40 cases in each group.The control group was treated with dapagliflozin,and the study group was treated with linagliptin on the basis of the con-trol group.The glucose and lipid levels and the total incidence of adverse reactions were compared between the two groups.Results After treatment,the level of glucose and lipid in the study group was better than the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the study group was 12.50%(5/40),which was slightly higher than that in the control group 7.50%(3/40),and the difference was not statistically significant(χ2=0.139,P>0.05).Conclusion Compared with dapagliflozin alone,dapagliflozin combined with linagliptin in the treatment of obese T2DM patients can more effectively improve the glucose and lipid levels of patients,and the safety is equivalent,without significantly increasing the risk of adverse reactions.
关键词
达格列净/利格列汀/肥胖/2型糖尿病/安全性Key words
Dapagliflozin/Linagliptin/Obesity/Type 2 diabetes mellitus/Safety引用本文复制引用
出版年
2025
NETL
NSTL
万方数据